Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

Reviva Pharmaceuticals Holdi / Equity Bottom-Up

<ul><li>Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications.</li><li>The candidates address multiple related mental disorders, rare diseases & other categories of un met need.</li><li>Reviva's lead indication in schizophrenia with brilaroxazine completed its Phase III RECOVER trial & may pursue future studies.</li></ul>

Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications.The candidates address multiple related mental disorders, rare diseases & other categories of un met need.Reviva's lead indication in schizophrenia with brilaroxazine completed its Phase III RECOVER trial & may pursue future studies.

<ul><li>Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications.</li><li>The candidates address multiple related mental disorders, rare diseases & other categories of un met need.</li><li>Reviva's lead indication in schizophrenia with brilaroxazine completed its 1st Phase III trial & is set to begin its 2nd in 2025.</li></ul>

Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications.The candidates address multiple related mental disorders, rare diseases & other categories of un met need.Reviva's lead indication in schizophrenia with brilaroxazine completed its 1st Phase III trial & is set to begin its 2nd in 2025.

<ul><li>Zacks Small-Cap Research Note for Reviva Pharmaceuticals Holdings, Inc. (RVPH)</li></ul>

Zacks Small-Cap Research Note for Reviva Pharmaceuticals Holdings, Inc. (RVPH)

RVPH: Open Label Extension Results & Key Opinion Leader Discussion

<ul><li>Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications.</li><li>The candidates address multiple related mental disorders, rare diseases & other categories of un met need.</li><li>Reviva's lead indication in schizophrenia with brilaroxazine (RP5063) completed its 1st Phase III trial & is set to begin its 2nd in 2025.</li></ul>

Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications.The candidates address multiple related mental disorders, rare diseases & other categories of un met need.Reviva's lead indication in schizophrenia with brilaroxazine (RP5063) completed its 1st Phase III trial & is set to begin its 2nd in 2025.

RVPH: M&A Deals Highlight Brilaroxazine Value

United States

Reviva Pharmaceuticals Holdings, Inc. operates as a clinical development pharmaceutical company. The Company focuses on developing a portfolio of internally discovered therapies that address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases. Reviva Pharmaceuticals Holdings serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Reviva Pharmaceuticals Holdi (RVPH US)

RVPH: Brilaroxazine Poster Presentations

Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications. The candidates address...

Zacks Small Cap Research

RVPH: There May Be A Faster Way

Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications. The candidates address...

Zacks Small Cap Research

RVPH: Open Label Extension Results & Key Opinion Leader Discussion

Zacks Small-Cap Research Note for Reviva Pharmaceuticals Holdings, Inc. (RVPH)

Zacks Small Cap Research

RVPH: 1Q:25 Results

Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications. The candidates address...

Zacks Small Cap Research

RVPH: M&A Deals Highlight Brilaroxazine Value

Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications. The candidates address...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)